CLAIMS

What is claimed is:

1. A composition comprising a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier.

~~2. The composition of claim 1, wherein the 5-HT_{2A} antagonist is also a 5-HT_{1A} receptor agonist.~~

2~~3~~. A ~~The~~ composition ~~of claim 1~~, comprising trazodone in a dosage range of 25-450 mg and bupropion.

3~~4~~. The composition of claim 2~~1~~, comprising trazodone in a dosage range of 25-450 mg and bupropion in a dosage range of 200-450 mg.

~~5. The composition of claim 1, comprising trazodone in a dosage range of 25-450 mg.~~

4~~6~~. A method of making a composition comprising combining a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier.

5~~7~~. The method of claim 4~~6~~, comprising combining bupropion, trazodone, and a pharmaceutically acceptable carrier.

6~~8~~. A method of treating ~~hypoactive~~ sexual ~~desire~~ disorder (~~H~~SD~~D~~) in a subject comprising administering to the subject a composition according to claim 2~~1~~.

7~~9~~. The method of claim 6~~8~~, wherein the ~~H~~SD~~D~~ is female orgasm disorder (FOD).

8~~10~~. The method of claim 6~~8~~, wherein the ~~H~~SD~~D~~ is female sexual arousal disorder (FSAD).

9~~11~~. The method of claim 6~~8~~, wherein the ~~H~~SD~~D~~ is sexual pain dysfunction.

10~~12~~. A method of treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject comprising administering to the subject a composition according to claim 2~~1~~.

11~~13~~. A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a composition according to claim 1.

12~~14~~. The method of any one of claims 6~~8~~, 10~~12~~ or 11~~13~~, wherein the composition is administered orally.

13~~15~~. The method of any one of claims 6~~8~~, 10~~12~~ or 11~~13~~, wherein the composition is administered topically.

14~~16~~. The method of any one of claims 6~~8~~, 10~~12~~ or 11~~13~~, wherein the subject is diagnosed and being treated for depression.

15~~17~~. The method of any one of claims 6~~8~~, 10~~12~~ or 11~~13~~, wherein the subject is not undergoing treatment for depression.

16~~18~~. The method of any one of claims 6~~8~~, 10~~12~~ or 11~~13~~, wherein the subject is concurrently prescribed an additional therapeutic agent.

17~~19~~. The method of any one of claims 6~~8~~, 10~~12~~ or 11~~13~~, wherein the subject is concurrently not prescribed an additional therapeutic agent.

18~~20~~. An extended release composition comprising a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier.

19~~21~~. The composition of claim 2~~1~~, wherein the composition is suitable for oral administration.

20~~22~~. The composition of claim 2~~1~~, wherein the composition is suitable for topical administration.

21~~23~~. A kit comprising a composition according to claim 2~~1~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating ~~H~~SD~~D~~ or symptoms thereof in the subject.

22~~24~~. A single dosage composition comprising a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier.

23~~25~~. A method of treating ~~hypoactive~~ sexual ~~desire~~ disorder (~~H~~SD~~D~~) in a subject comprising administering to the subject a 5-HT_{2A} antagonist and a norepinephrine-dopamine reuptake inhibitor.

24~~26~~. A method of treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject comprising administering to the subject a 5-HT_{2A} antagonist and a norepinephrine-dopamine reuptake inhibitor.

25~~27~~. A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a 5-HT_{2A} antagonist and a norepinephrine-dopamine reuptake inhibitor.

26~~28~~. A method of making a composition comprising combining a 5-HT_{1A} receptor agonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 of a 5-HT_{1A} receptor agonist and a norepinephrine-dopamine reuptake inhibitor.

27~~29~~. A method of making a composition comprising combining a 5-HT_{2A} antagonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 mg of a 5-HT_{2A} antagonist and a norepinephrine-dopamine reuptake inhibitor.